SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study

Ko, Tina; Dendle, Claire; Woolley, Ian; Morand, Eric F; Antony, Anna

doi:10.1080/21645515.2021.1958611

Cited by 30 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An Australian online survey among patients with rheumatic diseases regarding vaccination willingness reported that 65% were willing to have a COVID-19 vaccine [13]. While the actual vaccination rate is markedly higher in our cohort (80.1%), the online survey also showed that willingness was higher in patients with recent influenza and pneumococcal vaccination (OR 2.69) [13]. This finding was confirmed in our investigation, showing even higher odds (OR 6.372 for pneumococcal vaccination).…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study

2022

View full text Add to dashboard Cite

Background: In the second year of the COVID-19 pandemic, highly effective and safe vaccines became available. Since patients with rheumatic diseases show increased susceptibility to infections and typical medications raise the risk of severe COVID-19, high vaccination coverage is of significant importance to these patients. Methods: Consecutive patients with different rheumatic diseases were asked for their vaccination status regarding COVID-19, influenza and Streptococcus pneumoniae during their routine consultations. Any reported vaccination was validated with their personal vaccination card and/or by reviewing the CovPass smartphone app. Reasons for not having a COVID-19 vaccination were documented. Results: A total of 201 patients (mean age 62.3 ± 14.1 years) were included, the majority of them (44.3%) with rheumatoid arthritis, followed by spondyloarthritis (27.4%) and connective tissue diseases (21.4%). Vaccination coverage for SARS-CoV-2 was 80.1%; 85.6% got at least the first vaccination shot. Both valid influenza and pneumococcus coverage were associated with a higher probability of SARS-CoV-2 vaccination (odds ratio (OR) 6.243, 95% confidence interval (CI) 2.637–14.783, p < 0.0001 and OR 6.372, 95% CI 2.105–19.282, p = 0.0003, respectively). The main reason for a missing SARS-CoV-2 vaccination (70%) was being sceptical about the vaccine itself (i.e., the subjective impression that the vaccine was not properly tested and fear of unwanted side effects). Conclusions: Vaccination coverage against SARS-CoV-2 is high in patients with rheumatic diseases. Nevertheless, there are unmet needs regarding vaccination education to further increase vaccination rates.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study

2022

View full text Add to dashboard Cite

show abstract

“…Before the global distribution of COVID-19 vaccines, we observed substantial concerns among non-immunocompromised people about the lack of long-term research or the occurrence of adverse events after vaccination, and concerns among patients with immune-mediated inflammatory rheumatic diseases about interactions with their underlying autoimmune disease or immunosuppressive treatment regimens. 1 Our findings have since been replicated, 2 , 3 but there is as yet no data on how patients' thoughts and behaviour have evolved as vaccines were distributed, or data that compare COVID-19 vaccine coverage between patients with rheumatic immune-mediated inflammatory diseases and healthy controls.…”

mentioning

confidence: 82%

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

Boekel¹,

Hooijberg²,

Besten³

et al. 2022

The Lancet Rheumatology

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

“…The survey was adapted from a survey designed to examine vaccine hesitancy in rheumatic disease. 20 The investigators adapted the survey questions to be relevant to transplant recipients while ensuring they incorporated the three main domains of vaccine hesitancy determinants (confidence, complacency, and convenience), and the identified barriers and enablers to vaccine acceptance as specified by the WHO's SAGE vaccine hesitancy working group. 2 Questions were presented in yes/no, multiple choice, and 5-point Likert scale formats and assessed participant demographic and clinical characteristics, intention to receive vaccination, vaccine attitudes and understanding, information sources, and barriers and enablers of vaccination.…”

Section: Survey and Data Collectionmentioning

confidence: 99%

Kidney transplant recipients’ attitudes toward COVID‐19 vaccination and barriers and enablers to vaccine acceptance

Tharmaraj

Dendle

Polkinghorne

et al. 2021

Transplant Infectious Dis

Self Cite

View full text Add to dashboard Cite

Objective To identify barriers and enablers to COVID‐19 vaccination in renal transplant recipients who are undecided about vaccination. Methods An online survey was distributed to 876 adult kidney transplant recipients at a tertiary referral service, who had not been vaccinated against COVID‐19. The survey assessed willingness to be vaccinated, attitudes toward COVID‐19 vaccines, and barriers and enablers to proceeding with vaccination. Results The survey response rate was 54% (473/876). Three hundred and forty‐six (73.1%) participants planned to receive vaccination (yes group), 105 (22.2%) were undecided, and 22 (4.7%) refused vaccination. The undecided group were younger but were not different in other demographic characteristics to the yes group. The undecided group were less positive toward (34.29% vs. 91.3%, p < .001) and more concerned about (93.3% vs. 25.1%, p < .001) vaccination than the yes group. Their concerns related to vaccine safety (including harm to their transplant), poor efficacy, and a lack of rigorous testing in transplant recipients. Undecided recipients had received less vaccine‐specific information from medical specialists than the yes group. Most undecided participants (95.1%) were willing to proceed with vaccination with appropriate supports. The most desired supports were information and a recommendation to proceed with vaccination from their treating transplant specialist and team. Conclusion(s) Concerns about vaccine safety (including harm to transplant), poor vaccine efficacy, and lack of rigorous testing were barriers to vaccine uptake. Most undecided recipients would proceed with vaccination with specific recommendations and vaccine information provided by their transplant specialist/team. These simple interventions can be readily implemented to optimize vaccine uptake.

show abstract

SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study

Cited by 30 publications

References 28 publications

COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study

COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

Kidney transplant recipients’ attitudes toward COVID‐19 vaccination and barriers and enablers to vaccine acceptance

Contact Info

Product

Resources

About